Jim Frates: Yeah. Hey, Marc, it’s Jim. Yeah, the 10% of the patients that are receiving free drug is included. So those 10% are included in the net patients. Those are all the patients on therapy at the end of June. And yeah, free drug would be included in gross-to-nets — excuse me, free drug is actually in COGS, right? You’ve given the drug and you’re not getting any sales for it. So the free drug goes in COGS. Any patient assistance that we pay in terms of co-pay assistance or things like that that’s what goes in the gross-to-nets just to be clear on that. And then finally, in terms of July, I think we’ll comment on the July trends when we report our quarterly results for Q3. But I think our business is — with now three quarters under our belt, we’re all starting to get a chance to see what our business is like moving forward. But we won’t be giving specifics on July at this stage.
Marc Goodman: Great. Thanks.
Jim Frates: You bet.
Operator: The next question comes from Graig Suvannavejh with Mizuho. Please go ahead.
Graig Suvannavejh: Thanks so much. Congrats on the quarter. Just two questions. One maybe another way to ask a question that people seem to be trying to get at. Do you have any color on — or can you provide any color on kind of new prescription trends versus refill trends? Any metrics you can provide there and how that’s evolved? And then my follow-up is I’m curious about the expansion efforts to go beyond the ALS centers. And if you could perhaps put into context the portion of ALS prescribers that you’re targeting or that you hope to get that are outside of the ALS center setting. Thanks.
Justin Klee: So I’ll start and then have Margaret join in too. So again, we’re three quarters into launch. We have roughly 3,800 net people on treatment as of the end of Q2 which we’re very pleased about. I mean, that’s 3,800 people with ALS we’re helping. But that means that there’s many, many more people that we’d like to help as well. But I think we all here are constantly reminded of the mission at hand. And I think the ALS market in many ways is unique. And it’s because it’s a large rare disease, there’s a huge unmet medical need. And historically there have been few treatment options. And so I think the way that we’ve thought about our business, as Margaret was sharing, is to focus on the ALS specialists, and then continuing to look to broaden out. And so I think as we look at our prescription numbers, where our people have focused is where we’re seeing the prescriptions as well. And then Margaret, I’ll invite you to share any more details on that.
Margaret Olinger: Yeah. As we’ve indicated heavily focused at launch which I think was the right strategic decision to focus on the key ALS centers where the majority of ALS patients are actually treated. However, there’s also a number of ALS patients that are treated outside of ALS centers for multiple reasons, either they can’t transport, they can’t get there at a reasonable time and it’s — they typically need to go there every quarter to see the multidisciplinary care. There are a number of General and Community Neurologist, that are equally important to be educated and that’s where we’re expanding our focus. And we are continuing to increase our penetration and reach out to those, what we call our Tier A or B targets. And we’re just going to continue to work on that expansion moving forward, because it’s really important for us that every physician who treats an ALS patient is educated about the significant RELYVRIO benefits that we can bring to be able to serve this patient community optimally.
Operator: [Operator Instructions] And the next question comes from Ananda Ghosh with H.C. Wainwright. Please go ahead.
